Patent EP-2147982-A1 (EP)
Inventor: SEXTIUS PEGGY
IPC: G01N33/53
Filed: 2009-07-21
Abstract: Method for assessing epidermal homeostasis of skin of human subject comprises differential analysis of expression of at least two genes including genes of e.g. keratin 6B (KRT-6B), KRT16, estrogen-related receptor alpha (ESSRA), chromobox protein homolog 3 (CBX3), mitogen-activated protein kinase 5 (MAP3K5), triple functional domain protein (TRIO), phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta isoform (PIK3CD), and T cell receptor beta (TCRB), in response to a physical or chemical aggression of stratum corneum. Method for assessing epidermal homeostasis of skin of a human subject comprises differential analysis of expression of at least two genes including genes of keratin 6B (KRT-6B), KRT16, estrogen-related receptor alpha (ESSRA), chromobox protein homolog 3 (CBX3), mitogen-activated protein kinase 5 (MAP3K5), triple functional domain protein (TRIO), phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta isoform (PIK3CD), T cell receptor beta (TCRB), proline-rich Gla (G-carboxyglutamic acid) polypeptide 2 (PRRG2), microspherule protein 1 (ICP22BP), plasma glutathione peroxidase (GPX3), glucosidase beta acid (GBA), 2,3-bisphosphoglycerate mutase (BPGM), Nidogen-1 (NID1), (suppressor of mif two 3 yeast) homolog 2 (SMT3H2), lectin, galactoside-binding soluble 2 (LGALS2), down regulated in ovarian cancer 1 (DOC1), protein kinase C gamma type (PRKCG), Calgranulin A (S100A8), Calgranulin B (S100A9), S100 calcium-binding protein A2 (S100A2), S100A7, multi transmembrane protein (K15), small proline-rich protein 1B (cornifin) (SPRR1B), and gelsolin (GSN) in response to a physical or chemical aggression of stratum corneum. Independent claims are included for: (1) a method of diagnosis of the condition of the skin of the human individual comprising the assessment of the epidermal homeostasis of the skin of the individual; (2) a process for determining the efficacy of a treatment of a human individual skin, comprising evaluation of epidermal homeostasis of the skin before and after treatment by the method; (3) a process of screening of molecules for their beneficial effect on epidermal homeostasis, comprising the assessment of epidermal homeostasis of the skin of a human individual by the method before and after application of the molecule to be screened; (4) a process for testing treatments for their beneficial effect on the homeostatic barrier of human skin, comprising the evaluation of the homeostatic function of the skin of a human individual by the method before and after implementation of the treatment to be tested; and (5) a kit for evaluating epidermal homeostasis of the skin of human subject, comprising a means for carrying out a chemical or physical aggression of the stratum corneum, a means for carrying out a sampling of epidermis, a means for determining the level of expression of at least two genes comprising KRT6B, KRT16, ESSRA, CBX3, MAP3K5, TRIO, PIK3CD, TCRB, PRRG2, ICP22BP, GPX3, GBA, BPGM, NID1, SMT3H2, LGALS2, DOC1, PRKCG, S100A8, S100A9, S100A2, S100A7, K15, SPRR1B and GSN, and optionally, a means for determining the level of expression of at least one gene comprising S100A10, EIF1, actin-related protein 1 homolog A (ACTR1A), ribosomal protein L28 (RPL-28), RPL5, RPL35, ribosomal protein S-13 (RPS-13), RPS23, RPS16, RPL18, RPS15A, RPL7A, RPS28, GTPase activating protein (SH3 domain) binding protein 1 (G3BP1), thymosin, beta 4 X chromosome (TMSB4X), major histocompatibility complex, class I, C (HLA-C), dynein light chain LC8-type 1 (DYNLL1), nascent-polypeptide-associated complex alpha polypeptide (NACA), transforming protein RhoA (ARHA), brain-specific angiogenesis inhibitor 2 (BAI2), ubiquitin A-52 residue ribosomal protein fusion product 1 (UBA52) and guanine nucleotide binding protein (GNAS).